AICDA and Hodgkins lymphoma: HL as the sole or major NLRP3-AID associated feature is a recent and surprising finding that deserves attention, particularly since a targeted anti-IL-1 treatment is available that has been shown to be effective throughout the NLRP3-AID spectrum (5).